Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410169 | 0.78 | SMN1; SMN2 (0.44) | KDM4ENPC1PKMRAB9AHSD17B10 | |
| SCHEMBL308400 | 0.72 | LPO (0.55) | LPOBRD4KDM4ENPC1PKM | |
| SCHEMBL31153305 | 0.70 | LPO (0.52) | LPOBRD4KDM4ENPC1PKM | |
| Hydrochloric Acid SCHEMBL1806963 | 0.70 | LPO (0.52) | LPOBRD4KDM4ENPC1PKM | |
| Hydrochloric Acid SCHEMBL1410315 | 0.67 | HDAC8 (0.37) | L3MBTL1 | |
| SCHEMBL599433 | 0.67 | CCR1 (0.57) | KDM4ENPC1PKMRAB9AHSD17B10 | |
| SCHEMBL7538292 | 0.65 | — | — | |
| SCHEMBL13052883 | 0.65 | LPO (0.46) | LPOBRD4KDM4ENPC1PKM | |
| SCHEMBL30420079 | 0.65 | LPO (0.46) | LPOBRD4KDM4ENPC1PKM | |
| SCHEMBL23370195 | 0.63 | KDM4E (0.46) | LPOBRD4KDM4ENPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | Aeouls Sciences, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8546562-B2 | Substituted porphyrins | DUKE UNIVERSITY | 2013-10-01 | — | — | US | disclosed |
| US-20130189347-A1 | DISEASE TREATMENT DRUG | YUASA MAKOTO (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2601954-A1 | THERAPEUTIC AGENT FOR DISEASE | Yuasa, Makoto (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | AEOLUS SCIENCES, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8217026-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110065679-A1 | Substituted Porphyrins | AEOLUS PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2295435-A1 | Substituted porphyrins and their therapeutic use | National Jewish Health (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1616869-A1 | Substituted porphyrins and their therapeutic use | National Jewish Medical and Research Center (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1155019-B1 | SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE | NAT JEWISH MED & RES CENTER (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | MAKOTO YUASA (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-02-05 | — | — | US | disclosed |
| US-6544975-B1 | Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189347-A1 | DISEASE TREATMENT DRUG | PPOX, TFRC, SLC40A1 | LPO 32/4885BRD4 4029/4885KDM4E 3020/4885 |
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | LPO 4/4885BRD4 3933/4885KDM4E 3901/4885 |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | LPO 4/4885BRD4 3933/4885KDM4E 3901/4885 |
| US-20110065679-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | LPO 4/4885BRD4 3933/4885KDM4E 3901/4885 |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | TXN2, PRDX5, GPX4 | LPO 4/4885BRD4 3749/4885KDM4E 4317/4885 |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | LPO 4/4885BRD4 3933/4885KDM4E 3901/4885 |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | GPX4, FECH, PPOX | LPO 8/4885BRD4 4171/4885KDM4E 2437/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | LPO 2/4885BRD4 4017/4885KDM4E 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.